HomeCompareAMTY vs ABBV

AMTY vs ABBV: Dividend Comparison 2026

AMTY yields 5000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMTY wins by $62217131802825.25M in total portfolio value
10 years
AMTY
AMTY
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full AMTY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AMTY vs ABBV

📍 AMTY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMTYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMTY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMTY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMTY
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AMTY beats the other by $50,882,683,244,271,450,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMTY + ABBV for your $10,000?

AMTY: 50%ABBV: 50%
100% ABBV50/50100% AMTY
Portfolio after 10yr
$31108565901412.73M
Annual income
$29,930,990,143,689,118,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AMTY
No analyst data
Altman Z
-14.4
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMTY buys
0
ABBV buys
0
No recent congressional trades found for AMTY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMTYABBV
Forward yield5000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$62217131802825.35M$102.3K
Annual income after 10y$59,861,980,287,378,210,000.00$24,771.77
Total dividends collected$62057786341622.61M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AMTY vs ABBV ($10,000, DRIP)

YearAMTY PortfolioAMTY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$510,700$500,000.00$11,550$430.00+$499.1KAMTY
2$24,410,935$23,864,485.98$13,472$627.96+$24.40MAMTY
3$1,092,192,501$1,066,072,800.30$15,906$926.08+$1092.18MAMTY
4$45,746,366,951$44,577,720,975.17$19,071$1,382.55+$45746.35MAMTY
5$1,793,932,828,410$1,744,984,215,772.56$23,302$2,095.81+$1793932.81MAMTY
6$65,871,973,805,320$63,952,465,678,921.49$29,150$3,237.93+$65871973.78MAMTY
7$2,265,146,887,602,700$2,194,663,875,631,007.20$37,536$5,121.41+$2265146887.57MAMTY
8$72,954,689,148,998,180$70,530,981,979,263,280.00$50,079$8,338.38+$72954689148.95MAMTY
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$69,753$14,065.80+$2201076182660.81MAMTY
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$102,337$24,771.77+$62217131802825.25MAMTY

AMTY vs ABBV: Complete Analysis 2026

AMTYStock

Amerityre Corporation engages in the research and development, manufacture, and sale of polyurethane tires in the United States. The company provides closed-cell polyurethane foam tires for bicycles, golf and baggage carts, hand trucks, lawn and garden equipment, wheelbarrows, personnel carriers, and medical mobility products, as well as custom designed applications; polyurethane elastomer industrial tires for forklifts and scissor lifts; agricultural tires, including seeder tires and hay baler tires, as well as flat-free pivot tires that are used in irrigation systems; and specialty tires and tire-wheel assemblies. It serves original equipment manufacturers of lawn and garden products, and outdoor power equipment; regional tire distributors; retail cooperatives; agricultural tire distributors; and retailers of lawn and garden products, bicycle tires, and hand truck tires. The company was formerly known as American Tire Corporation and changed its name to Amerityre Corporation in December 1999. Amerityre Corporation was founded in 1995 and is headquartered in Boulder City, Nevada.

Full AMTY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AMTY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMTY vs SCHDAMTY vs JEPIAMTY vs OAMTY vs KOAMTY vs MAINAMTY vs JNJAMTY vs MRKAMTY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.